10:51 AM EST, 11/24/2025 (MT Newswires) -- YD Bio ( YDES ) said Monday its Exovisse Contact Lenses received the US Food and Drug Administration's 510(k) clearance for sales in the US through its partner 3D Global Biotech.

The lenses were cleared as a Class II medical device, while Exovisse Artificial Tears met FDA OTC Final Monograph M018 requirements for nationwide over-the-counter distribution, the company said.

YD Bio ( YDES ) said it enrolled its limbal stem cells and related exosomes in the FDA Drug Master File to support development of new therapies for retinal and macular disorders.

The company is also planning a clinical trial in Taiwan for dry eye treatment in collaboration with 3D Global Biotech and contract research firm YC Biotech, it added.

Shares of the company were up over 11% in recent trading.

Price: 9.37, Change: +0.92, Percent Change: +10.86